VYOME HOLDINGS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
VYOME HOLDINGS, INC. (HIND) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 4.10% for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-14.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2025-11-14
- VYOME HOLDINGS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2016-09-30 was 1.42%, a 9.55% decline year-over-year.
- VYOME HOLDINGS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2016-06-30 was 1.49%.
- VYOME HOLDINGS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2016-03-31 was 1.53%.
- VYOME HOLDINGS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2015-09-30 was 1.57%.
- VYOME HOLDINGS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2015 was 1.57%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|---|
| 2025-09-30 | 4.10% 10-Q · filed 2025-11-14 | |||
| 2025-06-30 | 5.20% 8-K · filed 2025-09-02 | |||
| 2024-09-30 | 5.20% 10-Q · filed 2025-11-14 | |||
| 2016-09-30 | 1.42% 10-Q · filed 2017-11-03 | |||
| 2016-06-30 | 1.49% 10-Q · filed 2017-08-02 | 1.49% 10-Q · filed 2017-08-02 | ||
| 2016-03-31 | 1.53% 10-Q · filed 2017-05-10 | |||
| 2015-12-31 | 1.57% 10-K · filed 2018-03-05 | |||
| 2015-09-30 | 1.57% 10-Q · filed 2016-11-10 | 1.57% 10-Q · filed 2016-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |